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AbstrAct
Aims: contradictory information exists on 
whether different clinical guidelines are effective 
in detecting the malignant risk in patients 
with pancreatic cysts. We have retrospectively 
evaluated the accuracy and the long-term 
outcome in patients with pancreatic cysts with 
a diameter ≥ 2 cm when indication for surgery 
was established by clinical evaluation of their 
malignant risk according to sendai clinical 
Guidelines associated to endoscopic-ultrasound-
fine-needle aspiration. Methods: Patients with 
pancreatic cysts with a diameter ≥2 cm were 
evaluated for their potential malignant risk by 
endoscopic-ultrasound-fine-needle aspiration 
associated to the clinical evaluation by sendai 
clinical Guidelines. Long-term outcome and 
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comparison in patients survival as well as 
the accuracy in detecting malignancies were 
evaluated with the combined clinical and 
endoscopic evaluation. results: two hundred 
eighteen patients with pancreatic cysts were 
observed during a 9-year period of the study 
and 74 of them (33.9%) presenting with a 
pancreatic cyst ≥ 2 cm were eligible for the study. 
Fourteen malignant neoplasms (18.9%) were 
detected. the accuracy in detecting malignancy 
of combined clinical and endoscopic evaluation 
was very high (0.99). the five-year survival 
rates for patients who underwent surgery with 
benign and malignant pancreatic cysts and 
for patients in observational follow-up were 
similar (70% and 85%). the cohort of patients 
with malignant pancreatic cysts with ductal 
adenocarcinoma showed a five-year survival rate 
of 41%. conclusion: Endoscopic ultrasound fine-
needle aspiration associated to sendai clinical 
guidelines showed a high accuracy in detecting 
malignant risk in patients with pancreatic cysts 
with a diameter ≥ 2 cm. allowing appropriate 
selection for surgical treatment with satisfactory 
long-term survival. 
Keywords: Diagnostic imaging, Pancreatic cancer, 
Pancreatic carcinoma, Pancreatic neoplasm, Pan-
creatic pseudocyst
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iNtrODUctiON
With the increasing current use of advanced 
abdominal images modalities such as cross-sectional 
imaging modalities by computed tomography (CT) and 
magnetic resonance imaging (MRI), pancreatic cysts 
(PCs) are commonly encountered. 
As these lesions have become a common finding, 
the different types of PCs pose a challenging diagnostic 
dilemma to assess the potential for malignancy within a 
cyst [1, 2]. 
Whereas some lesions show benign behaviour, such as 
serous cystadenomas (SCA) and pancreatic pseudocysts 
(PPC), others have an unequivocal malignant potential, 
such as mucinous cystic neoplasm (MCN), main duct 
(MD) or mixed type (MT) intraductal papillary mucinous 
neoplasm (MD/MT-IPMN), solid pseudo-papillary 
neoplasm (SPPN), pancreatic neuroendocrine neoplasm 
(PNEN) and, to a lesser extent, some branch duct IPMN 
(BD-IPMN). 
Endoscopic-ultrasound-fine-needle aspiration (EUS-
FNA),  allows for analysis of the cyst content, has been 
increasingly shown to improve the preoperative diagnosis 
in the majority of patients with undetermined PCs. The 
overall accuracy rates of EUS in differentiating neoplastic 
versus non-neoplastic lesions range from 40–93%, so 
EUS imaging features alone for PCs seem insufficient to 
make a diagnosis [3]. 
The 2006 Sendai Consensus Guidelines (SCG) [4] 
and the revised Fukuoka Consensus Guidelines (FCG) 
in 2012 established that patients with presumed but 
not proven mucinous cystic neoplasm should undergo 
surgical resection when high-risk stigmata are present 
[5]. However, these recommendations were established 
for mucinous cystic neoplasm and not for all PCs [6].
Other guidelines were suggested by the American 
College of Gastroenterologist (ACG) in 2007 [7] and 
more recently, in 2013, the European Expert Consensus 
(EEC) [8] stated that unless major contraindications 
were present, surgical resection should be considered 
in all symptomatic patients and in patients with MCN 
and MD/MT-IPMN with HRS or with evidence of some 
defined “worrisome features”. Recently, the American 
Gastroenterological Association (AGA) revised their 
previous guidelines, which were labelled as evidence-
based rather than consensus-based [9]. However some 
investigators have expressed concern over whether 
adopting the AGA guidelines will result in low accuracy in 
identifying advanced neoplasia [10, 11].
Although outcomes after pancreatic surgery have 
improved over the last decades, this type of surgery still 
remains complex, with high morbidity and mortality 
ranging from 2–15% [12]. In contrast to ductal 
adenocarcinoma, cystic neoplasms with malignant 
potential are slow-growing, and a more favourable 
prognosis has been reported for these neoplasms, even in 
the setting of malignant degeneration [13]. 
Efforts to effectively and correctly identify those 
patients who might benefit from surgery and to identify 
other patients who would benefit from surveillance 
without therapy lack evidence by survival comparisons for 
the different classes of risk. We hypothesize that the EUS-
FNA will yield high positive and high negative predictive 
values when applied to unselected consecutive patients 
affected by PCs with a minimum diameter ≥ 2 cm. The 
primary aim of this study was to critically evaluate the 
clinical utility and accuracy of the EUS-FNA in association 
with the SCG in malignant risk prediction of all PCs. The 
secondary aim of this study was to evaluate the natural 
course of all patients with PCs describing the outcome of 
different cohorts of patients and their long-term survival 
when they were stratified for the presence of benign or 
malignant PCs, and when they were submitted to surgical 
treatment or to clinical surveillance without treatment. 
MAtEriALs AND MEtHODs
Patients
From January 2007 to October 2015, 218 consecutive 
patients with undetermined PCs were admitted at 
Niguarda Hospital in Milan. Patients with a reported 
cytological or histological diagnosis referred to our 
Institution from other centers were excluded. Seventy four 
patients presenting with a PC ≥ 2 cm with undetermined 
diagnosis and with initial radiological features of 
suspected mucinous cysts were eligible and included in 
the study receiving full clinical evaluation following SCG 
and EUS-FNA. Informed consent was obtained from all 
patients before performance of EUS-FNA according to 
the protocol approved by our Institutional Review Board 
and by the Regional Ethics Committee.
Patients with PCs smaller < 2 cm were excluded 
from the study and underwent a six months based 
follow up. A prospective database with all clinical and 
radiological data was first created in 2007 according the 
SCG. Furthermore all morphological, biochemical and 
cytological findings available with EUS-FNA were also 
recorded in the same database. At the end of the study all 
clinical and pathological features of the 74 patients were 
retrospectively reviewed by a multidisciplinary team. 
stratification of malignant risk according to 
scG
Malignant risk was evaluated using radiological 
evaluation by US, CT-Scan, Magnetic resonance imaging 
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(MRI) or magnetic Resonance Cholangiopancreatography 
(MRCP) and all relevant clinical findings. Patients were 
stratified into two classes of risk: high risk (HR) and 
low risk (LR) patients according to the SCG. According 
to the SCG, all patients with PCs showing high risk 
stigmata were considered at HR for malignancy if they 
had symptoms attributable to the cyst, if the cyst size was 
> 3 cm irrespective of symptoms, or if the cysts were < 3 
cm in size with suspicious features such as the presence of 
symptoms, solid components like mural nodules and/or a 
dilated main pancreatic duct > 6 mm. All PCs that did not 
meet these criteria for high risk stigmata were classified 
as LR.
stratification of malignant risk and the 
EUs-FNA procedure
After evaluation with SCG all patient underwent 
EUS-FNA by a gastroenterologist of the Interventional 
Endoscopy Service who was blind to the previous 
evaluation. In all patients a new evaluation was obtained 
by adding EUS-FNA imaging information (size, location, 
septations, mural nodules, mass component, main 
duct communication, borders, and invasiveness) to the 
previous clinical and radiological work up. The cyst fluid 
content was evaluated for cytological analysis and for 
chemical and physical characteristics. Intralesional CEA 
level were determined only when sufficient cyst fluid was 
obtained in order to better differentiate mucinous from 
non-mucinous cysts with the usual cut-off value of 192 
ng/mL suggested by some Authors (2-9) .
According to Pitman’s criteria [14] cytology was graded 
as: stage I-II-III-IV: non-diagnostic, atypical, negative 
for malignant and neoplastic benign; stage V, suspicious 
for malignancy; stage VI, positive for malignancy. 
Based on these findings, only patients with cytology 
at stage V and VI were considered at HR and were 
considered possible candidates for curative surgery. 
When none of these criteria were present (stage I, II, III, 
IV) patients were considered at LR and submitted to a 3-6 
months interval of surveillance depending on the cyst size 
and on the clinical course.
Patients with SCG considered at HR but with adequate 
cytology negative for malignant cells were considered at 
LR and received 3-months-based follow up. The technique 
of EUS-FNA has been previously described in detail [15]. 
The fine needle biopsy procedure was repeated until 
sufficient material was aspirated. The needles normally 
used were the same as those for solid lesions, 19 and 22 
gauge. 
Definitive diagnosis
In all patients the definitive diagnosis was obtained 
by cytological examination and or surgical specimen. The 
30 items of the STARD 2015 (Standards for Reporting of 
Diagnostic Accuracy Studies Statements) were observed 
as guiding principles [16]. For all patients a definitive 
diagnosis of malignant or of benign PC was reviewed at the 
end of follow-up by a multidisciplinary team composed by 
a cytohistopathologist, surgeon, and gastroenterologist 
and it was strictly based on the histological specimen in 
all patients submitted to surgery or on cytological criteria 
obtained by EUS-FNA in other patients. 
classification of Pcs
According to the WHO classification [17] all lesions 
were classified as follows: mucinous neoplasm (MCN), 
serum cyst adenoma (SCA), main-duct/mixed type 
intraductal papillary mucinous neoplasm (MD/MT-
IPMN), branched-duct intraductal papillary mucinous 
neoplasm (BD-IPMN), pancreatic pseudocysts (PPC), 
pancreatic neuroendocrine neoplasm (PNEN), solid 
pseudopapillary neoplasm (SPN), and pancreatic duct 
adenocarcinoma (PDAC). As suggested by the Japanese 
Pancreas Society, the latter group was subdivided into 
IPMN-derived pancreatic duct adenocarcinoma (IPMN-
DPDAC) and IPMN-concomitant pancreatic duct 
adenocarcinoma (IPMN-CPDAC) [18].
indication for surgery 
Our recommendation was to resect PCs in those 
patients at HR for malignancy after EUS-FNA evaluation 
provided that patients were considered good surgical 
candidates with a reasonable life expectancy.
Despite some patients were considered at LR surgery 
was considered in those patients with major symptoms 
suffering from recurrent abdominal pain or back pain 
unrelated to other causes, or in the presence of recurrent 
pancreatitis, worsening diabetes, jaundice and weight 
loss or gastro-duodenal outlet obstruction due to extrinsic 
compression by the PC. All other patients with PCs who 
did not meet these criteria or classified at LR underwent 
clinical surveillance. 
Outcome evaluation and statistical analyses
Accuracy, sensitivity, specificity, negative and positive 
predictive value of combined SCG and EUS-FNA evaluation 
were calculated by using standard 2x2 contingency 
tables; the definitive histological or cytological diagnosis 
(reference standard) was considered to classify all PCs 
as malignant or benign lesion; detection of HR (possible 
malignant neoplasm) or LR (possible benign neoplasm) 
at the time of provisional diagnosis was obtained after 
the combined two steps evaluation with SCG associated 
to EUS-FNA. The overall survival curve was calculated 
for the group of 74 patients and was calculated from the 
time of first EUS-FNA. A Kaplan-Meier survival analysis 
comparison was performed for the cohort of patients who 
underwent surgery and for the cohort of patients who 
underwent clinical surveillance. Statistical analysis by 
survival comparison was obtained between two cohorts 
of patients with benign and malignant PCs. Differences 
in survival curves were compared by log-rank testing 
(Mantel-Cox). Statistical significance was determined at 
P < 0.05.
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rEsULts
Seventy-four patients presented with 38 PCs in the 
head, 24 in the body and 12 in the tail of the pancreas. 
Nine patients of 74, originally excluded from the study 
with a small PC (< 2 cm) showed progression of the PC 
diameter during the follow up and were subsequently 
included in the study. No major complications were 
registered after the EUS-FNA procedure. According 
to Common Terminology Criteria for Adverse Events 
(CTCAE) 4 patients had mild early complications: 2 
patients presented fever and 2 mild pancreatitis (amylase 
increased to at least three times the normal values in 
addition to abdominal pain); one patient had moderate 
grade 1 complication (intracystic bleeding after complete 
fluid evacuation). All complications resolved with medical 
therapy, within 3 days. 
Twenty-five patients underwent surgery and histology 
was obtained from surgical specimen or by surgical 
biopsy of the lesion. EUS-FNA cytology was diagnostic 
in 69 of 74 patients. Sufficient fluid for intracystic CEA 
determination was available only in 31 patients (40%) 
and was not considered in our analysis. Two patients 
of 74 with radiological progression of disease who had 
nondiagnostic cytology, were submitted to a second 
attempt by EUS-FNA: both patients underwent surgery 
and only in one patient a malignant cytology coul be 
evidenced. 
Table 1 summarizes the distribution of different 
types of PCs for the 74 patients (MCN, SCA, MD/MT- 
IPMN, BD-IPMN, PPC, IPMN-DPDAC, IPMN-CPDAC 
and PNEN) according to age, sex and presence of high-
risk stigmata evaluated by SCG/EUS-FNA, number of 
diagnostic cytological diagnoses available, and diameter 
of the lesions.
Accuracy, positive and negative predictive 
value
In Table 2 are reported accuracy, sensitivity, specificity, 
positive and negative predictive value obtained with SCG 
and EUS-FNA evaluation in detecting malignant PCs 
when histological or cytological diagnosis is taken as the 
reference standard. 
Malignant Pcs 
In 14 patients (18,9%), a malignant tumour was 
diagnosed (10 pancreatic ductal adenocarcinoma and 
4 neuroendocrine tumours). Ten of 14 patients with 
malignancy were considered clinically fit and were 
submitted to surgical treatment; four patients deemed 
unfit for surgery were followed up by oncologists and 
gastroenterologists with the best available medical 
treatment. 
Table 1: Definitive diagnosis of PCs in 74 patients according to age, sex, presence of high risk stigmata (HRS) according to SCG, 
diagnostic versus non-diagnostic cytology, diameter of the lesions. The distribution of definitive diagnoses is expressed in decreasing 
order for different PC frequencies.
Definitive diagnosis N. Patients
(%)
Age
(range)
sex
M/F
Hrs according to 
scG-EUs-FNA
Diagnostic
cytology with 
EUs-FNA
Diameter 
(mean value 
in mm)
SCA 20
(27)
27–89 11/9 0 18 37.6 ± 13.3
PPC 17
(22)
34–78 13/4 0 17 101 ± 50.9
MCN 15
(20)
44–79 8/7 4 14 33.7 ± 12.1
IPMN-DPDAC 8
(10.8)
48–82 5/3 5 7 53.6 ± 19.3
MD/MT- IPMN 4
(5.4)
59–83 2/2 1 4 25.7 ± 3.1
BD-IPMN 4
(5.4)
48–87 1/3 0 3 23.2 ± 0.31
PNEN 4
(5.4)
44–68 2/2 4 4 33.3 ± 12.1
IPMN- CPDAC 2
(2.7)
66–69 1/1 1 2 38±5.11.0
Overall 74 27–89 43/31 15 69 49.5±24.5
Abbreviations: SCA Serous Cystadenoma; PPC Pancreatic Pseudocyst, MCN Mucinous Cystic Neoplasm, MD/MT-IPMN Main 
Duct or/and Mixed Type-Intraductal Papillary Mucinous Neoplasm, BD-IPMN Branched Duct-Intraductal Papillary Mucinous 
Neoplasm, IPMN-DPDAC IPMN-Derived Pancreatic Duct Adenocarcinoma, IPMN-CPDAC IPMN-Concomitant Pancreatic Duct 
Adenocarcinoma, PNEN Pancreatic Neuroendocrine Neoplasm
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surgical treatment 
A total of 25 of 74 patients underwent surgery. 
Major surgical resections with curative intent (6 
pancreaticoduodenectomy and 4 distal pancreatectomy) 
were performed in 10 patients evaluated at high risk for 
malignant lesions (5 IPMN-DPDAC, 2 IPMN-CPDAC 
and 3 PNEN). Fifteen patients with symptomatic benign 
PCs (8 PPC, 4 MCN, 2 with SCA, 1 with MD/MT-IPMN) 
were submitted to pseudocyst-jejunostomy, pseudocyst-
gastrostomy, distal pancreatectomy or atypical 
pancreatectomy.
survival
At the end of follow-up, 62 of 74 patients are alive with 
a mean follow-up for all patients of 46.7 months. The 
overall survival rate for all patients was 93% at 1 year, 85% 
at 3 years, and 80% at 5 years (Figure 1). The survival rate 
for patients with benign PCs, with the neuroendocrine 
tumours and with malignant ductal adenocarcinoma was 
respectively 94%, 100% and 85% at 1 year, 90%, 100% 
and 41% at 3 years and 85%, 70% and 41% at 5 years; 
the difference in survival rate for patients with benign 
or neuroendocrine tumours when compared with that 
of patients with malignant ductal adenocarcinoma was 
statistically significant (P < 0.005 by log-rank testing, 
Fig 2). The survival rate of patients who underwent 
observational follow-up or surgical procedures was, 
respectively, 93% and 93% at 1 year, 90% and 80 % at 
3 years, 85% and 70% at 5 years (N.S. P > 1 by log-rank 
testing, Figure 3).
DiscUssiON
PCs represent a wide collection of tumours with 
different malignant potential at clinical presentation, and 
the correct choice between surgical excision and follow-
up without therapy is a challenging topic of debate. The 
majority of patients discovered to have a PC is completely 
asymptomatic and the estimated prevalence in the 
general population is around 3.5 % [19].
Several diagnostic modalities involving cross-
sectional radiological imaging or endoscopy are useful 
for narrowing down the diagnosis and can give evidence 
to propose surgery or surveillance [20, 21]. However, a 
definitive diagnosis is often difficult without supporting 
cytological or histological evidence by means of EUS-
FNA or surgical resection. The majority of the guidelines 
and recommendations proposed during last ten years 
Figure 1: Overall survival rate for all patients with PCs
Figure 2: Survival rate for patients with benign PCs (dotted 
line), with neuroendocrine tumours (continuous thin line), 
and with ductal adenocarcinoma (continuous thick line). (P < 
.005 by log-rank testing between benign PCs or neuroendocrine 
tumours when compared with ductal adenocarcinoma).
Table 2: Accuracy, sensitivity, specificity, positive and negative predictive values obtained with combined SCG and EUS-FNA in 
detecting malignant PCs when histological or cytological diagnosis is taken as reference standard.
Accuracy sensitivity specificity Positive Predictive Value 
Negative Predictive
Value 
scG with EUs-FNA 0.99 1  0.98  0.93 1.0
[4–7] were designed specifically for the management of 
MCNs and IPMNs, and the major assumption was that 
all patients with MD/MT-IPMNs and MCNs with so 
called “high risk stigmata” according to SCG in 2006 (or 
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“worrisome features” according to FCG in 2012) should be 
considered for resection, whereas patients with selected 
non-malignant BD-IPMNs could be observed. However, 
a preoperative diagnosis of a MCN or IPMN is frequently 
unavailable, especially via cross-sectional imaging 
features alone. For that reason, the clinical application of 
these guidelines remains limited, especially in the initial 
triage of those patients who present with an incidental PC, 
due to the difficulty in distinguishing not only between 
MCNs and IPMNs but also between mucinous PCs and 
other PCs, such as SCA, PPC, and PNEN [22, 23].
The first aim of our study was to investigate the 
potential malignant risk of all undetermined PCs with a 
diameter ≥ 2 cm during an nine-year period with EUS-
FNA in association with the conventional clinical and 
radiological work up proposed by SCG in 2006. The 
choice to limit our study to patients with PCs with a cut-
off diameter of ≥ 2 cm, although arbitrary, was suggested 
by the very low yield of FNA for cysts < 1.5 cm and by 
the reported lower risk of malignancy for small cysts [24]. 
When international clinical guidelines are utilized (SCG, 
FCG, ACG, AGA, EEC) different results have been also 
reported with lower positive predictive values ranging 
from 29–66%, [25]. These findings may suggest that if 
international guidelines were applied during the early 
triage of patients with PCs, in one out of three patients 
potentially submitted to surgical resection, no malignancy 
can be found despite the fact that the hazard ratio of 
pancreatic cancer risk in those patients has been evaluated 
to be significantly higher when compared with the rest 
of patients without cysts [26]. In our study we registered 
only one false positive malignant risk evaluation in one 
symptomatic patient who was submitted to surgery for 
jaundice and gastric outlet obstruction.
The second aim of our study was to follow up and verify 
the outcome of all patients with benign and malignant 
disease as well as the outcome of patients who underwent 
surgical treatment during the 9-year study period. A 
considerable overall survival rate for the 14 patients 
with malignant PCs was observed (41% at fifth year for 
10 patients with ductal adenocarcinoma and 70% at fifth 
year for four patients with neuroendocrine tumours). The 
survival rate of patients with ductal adenocarcinoma was 
41%. This was statistically inferior to that observed in 
patients with benign PCs (85% at fifth year). However, 
the observation of a 41% survival rate for patients with 
ductal adenocarcinoma might support the fact that the 
natural course of the malignant pancreatic cysts seems 
more favourable when compared to that of other form of 
non cystic presentation of pancreatic adenocarcinoma, 
in which usually less than 30–40% of patients usually 
survive after five years [27]. Major technical controversies 
exist concerning the diagnostic yield of EUS. These lie in 
the fact that it is virtually impossible to acquire adequate 
fluid for the examination of cysts less of than 15 mm, 
and it is impossible to aspirate fluid from, on average, 
half of the cysts, either because the solid component 
predominates (as in the case of microcystic SCA) or 
because the IPMN has a highly viscous content [28]. The 
use of a 19 and 22-gauge needle was associated with a low 
rate of complications (6.75%) in accord with other clinical 
reports [29] and enabled us to obtain adequate diagnostic 
cytological material in 69 patients of 74 (93%); in the 
remaining patients the histological surgical specimen was 
available. 
A PNEN was found in 4 patients (5.4%); this finding 
is similar to that reported in the literature (8%) and 
seems to be clinically relevant, considering that PNENs 
are relatively rare lesions and that most of these 
tumors are clinically non-functioning [30]. PNEN is a 
hypoechoic tumor with overt vascularity. Sometimes, this 
hypoechoic image can be confused with an anechoic cyst. 
However, the vascularization of the septa in a cyst might 
be confounding. In the case of cystic degeneration of a 
PNEN, the differential diagnosis should always require 
the support of EUS-FNA. 
cONcLUsiON
Despite some limitations due to the retrospective 
nature and to the small sample of patients, our study 
seems to support the clinical utility of the endoscopic-
ultrasound-fine-needle aspiration (EUS-FNA) as a 
valid diagnostic tool in association to Sendai Consensus 
Guidelines (SCG) evaluation. Combining clinical 
evaluation by SCG and endoscopic, morphological and 
cytological information by EUS-FNA a high accuracy, 
high positive and high negative predictive value are 
Figure 3: Survival rate of patients who underwent surgical 
procedures (dotted line) or observational follow-up (N.S. P > .1 
by log-rank testing).
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obtained which allows appropriate selection of patients 
with suspected malignant PCs who can benefit for surgery 
avoiding unnecessary, high-risk surgical procedures for 
many other patients. EUS-FNA associated to SCG can 
be recommended during the early diagnostic stage of 
patients with pancreatic cysts ≥ 2 cm allowing appropriate 
selection of those patients with a high malignant risk for 
surgical treatment with satisfactory long term survival. 
Further prospective multicenter studies could better 
evaluate the real advantage of EUS-FNA with other 
different proposed clinical guidelines.
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